Narrative review on ICIs in patients with viral infections and solid tumors
This is a narrative review that synthesizes evidence on the use of immune checkpoint inhibitors (ICIs) in patients with viral infections, including hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human papillomavirus, and Epstein–Barr virus, who have solid tumors. The authors discuss how viruses reconfigure tumor immune landscapes, leading to heterogeneity in immunotherapy responses.
Key synthesized findings include potential effects on antitumor immune function, virological responses, and immunological changes suggestive of improved viral control. The review also addresses the risk of viral reactivation and immune-related adverse events (irAEs). However, no specific pooled effect sizes, sample sizes, or comparative outcomes are reported, as this is a qualitative synthesis.
The authors note limitations, including the risk of viral reactivation as a persistent concern. They emphasize the potential value of virus-specific immune profiling to guide individualized treatment strategies and the need to optimize the integration of ICIs with antiviral therapies.
Practice relevance is restrained, focusing on the need for careful patient selection and monitoring. The review does not provide trial-level details on interventions, comparators, or adverse event rates, and it calls for further research to clarify safety and efficacy in this population.